Editas Surpasses Therapeutic Gene Editing Threshold in New Preclinical Data
Editas Medicine, Inc. (NASDAQ:EDIT) ranks among the best CRISPR stocks to buy. At the European Hematology Association 2025 Congress on June 12, Editas Medicine, Inc.
Editas Medicine Inc. (EDIT)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Millennium Management Israel Englander | 1,876,440 | $4,128,168 | +558% | 0% |
| 2. | Two Sigma Advisors John Overdeck And David Siegel | 940,600 | $2,069,320 | -23% | 0% |
| 3. | Renaissance Technologies Jim Simons | 888,400 | $1,954,480 | -14% | 0% |
| 4. | Woodline Partners Michael Rockefeller And Karl Kroeker | 846,399 | $1,862,078 | 0.01% | |
| 5. | AQR Capital Management Cliff Asness | 767,615 | $1,688,754 | -25% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.64 | 45,000 | $253,867.50 | 67,700 | 2024-05-13 | Filing | |
| $45.51 | 5,800 | $263,969.60 | 22,700 | 2021-03-03 | Filing | |
| $46.27 | 25,000 | $1,156,800.00 | 35,000 | 2021-03-02 | Filing | |
| $23.94 | 10,200 | $244,188.00 | 16,900 | 2019-03-05 | Filing | |
| $38.03 | 10,000 | $380,252.00 | 10,000 | 2018-05-18 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.58 | 679 | $1,751.82 | 16,827 | 2025-08-07 | Filing | |
| $2.49 | 5,121 | $12,756.92 | 64,398 | 2025-07-31 | Filing | |
| $1.72 | 446 | $768.90 | 17,506 | 2025-06-03 | Filing | |
| $1.72 | 726 | $1,251.84 | 69,519 | 2025-06-03 | Filing | |
| $1.72 | 15,192 | $26,195.57 | 280,282 | 2025-06-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 7,159,492 | $15,750,883 | 0% | |
| 2. | 6,820,854 | $15,005,879 | 0% | |
| 3. | 1,964,298 | $4,322,541 | 0% | |
| 4. | 1,846,869 | $4,063,112 | 0% | |
| 5. | 1,420,683 | $3,125,503 | 0% |
News See All
Top 10 CRISPR Stocks to Buy Now
Innovation is a hallmark of the biopharmaceutical sector, which is fueled by the demand for novel therapies to address unresolved medical needs.
Top 11 CRISPR Stocks to Invest In
The pharmaceutical industry is buzzing with innovation, driven by the need for new treatments, tackling unmet medical challenges, and leveraging cutting-edge technologies like pharmacogenomics, digital...
10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds
The pharmaceutical industry remains a hub of patent innovation, driven by evolving treatment paradigms, unmet medical needs, and the rising influence of technologies like pharmacogenomics, digital therapeutics...
Editas Medicine, Inc. (NASDAQ:EDIT) Q2 2024 Earnings Call Transcript
Operator: Good morning and welcome to the Editas Medicine’s Second Quarter 2024 Conference Call. All participants are now in a listen-only mode.
10 Best Biotech Penny Stocks to Buy Now
In 2024, the healthcare industry has been doing well, encouraging investors to look into new and exciting opportunities.
Top 10 Small-Cap Stocks with Highest Upside Potential
Most giant companies start as small-cap, but by continuously developing and growing their earnings, their share price increases making them large or mega-cap companies, and along the way smart investors...
Editas Medicine, Inc. (NASDAQ:EDIT) Q1 2024 Earnings Call Transcript
Editas Medicine, Inc. misses on earnings expectations. Reported EPS is $-0.76 EPS, expectations were $-0.63. Editas Medicine, Inc.
12 Under-the-Radar Stocks With Massive Upside for 2024
In this piece, we will take a look at the 12 under the radar stocks with massive upside for 2024.
Editas Medicine, Inc. (NASDAQ:EDIT) Q4 2023 Earnings Call Transcript
Editas Medicine, Inc. beats earnings expectations. Reported EPS is $-0.23, expectations were $-0.52.
Billionaire Hedge Funds
